BUFFALO, N.Y., May 15, 2017 /PRNewswire/ -- Tactiva Therapeutics, a development stage company targeting a broad range of cancers, announced today positive data on the effects of their novel autologous cellular immunotherapy. Built on a dual enhanced adoptive cell therapy (DEACT™) platform, the company's engineered CD4/CD8 cells generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells. The results were presented at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), May 10-13, 2017 in Washington, D.C.
"This study demonstrates that our T cell immunotherapy, built on our dual enhanced adoptive cell therapy platform, enhances the immune response to various solid tumors in animal models," said Richard Koya, M.D., PhD. Associate Professor of Oncology, Roswell Park Cancer Institute. "Our proprietary approach leveraging a combined adoptive cell transfer demonstrates a durable and sustained ability to produce an endless supply of CD4 cells, which will work as a sentry against cancer cells."
The results of the study indicate that in NSG (NOD scid gamme) mice, among the most highly immunodeficient mice, challenged with melanoma and ovarian cancers, Tactiva's autologous cellular immunotherapy provides remarkable tumor control (up to 6-fold magnitude) with sustained differentiation and proliferation compared with the control groups.
"These data support our commitment to advancing the clinical development of our DEACT platform as an immuno-oncology therapy for many types of cancer," said Matt Colpoys, Tactiva CEO. "Based on these study findings, we are pursuing a phase I/IIa clinical trial to evaluate the safety, tolerability and preliminary efficacy of DEACT as an autologous cellular immunotherapy that produces a durable and sustained response to tumor burden challenge."
Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. More information about the company, its technology, and products can be found on its web site at www.tactivatherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tactiva-therapeutics-presents-positive-data-on-novel-dual-cd4cd8-t-cell-receptor-in-preclinical-models-of-cancer-300457319.html
SOURCE Tactiva Therapeutics